An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction

Journal of Thrombosis and Thrombolysis

Volumn 30, Issue 3, 2010, Pages 358-364

  Carlquist, John F ^a,b   Horne, Benjamin D ^a,b   Mower, Chrissa ^a   Park, James ^a   Huntinghouse, John ^a   McKinney, Jason T ^c   Muhlestein, Joseph B ^a,b   Anderson, Jeffrey L ^a,b  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c Idaho Technology Inc   (United States)

Author keywords

Anticoagulation; CYP2C9; CYP4F2; Genetics; Pharmacogenetics; VKORC1; Warfarin

Indexed keywords

APOLIPOPROTEIN E; CYTOCHROME P450; CYTOCHROME P450 F2; EPOXIDE HYDROLASE; OXIDOREDUCTASE; OXYGENASE; PROTEIN C; PROTEIN CALU; PROTEIN EPHX1; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

AGED; ARTICLE; DRUG MECHANISM; DRUG METABOLISM; FEMALE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; APOLIPOPROTEINS E; ARYL HYDROCARBON HYDROXYLASES; CALCIUM-BINDING PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE; EPOXIDE HYDROLASES; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MICE; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN C;

EID: 77957959128     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-010-0467-3     Document Type: Article

References (26)

1. EA Sconce TI Khan HA Wynne P Avery L Monkhouse BP King P Wood P Kesteven AK Daly F Kamali 2005 The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen Blood 106 7 2329 2333 1:CAS:528:DC%2BD2MXhtVKqt7%2FL 10.1182/blood-2005-03-1108 15947090 (Pubitemid 41510803)
2. M Vecsler R Loebstein S Almog D Kurnik B Goldman H Halkin E Gak 2006 Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin Thromb Haemost 95 2 205 211 1:CAS:528:DC%2BD28XisVSrtLw%3D 16493479
3. JF Carlquist BD Horne JB Muhlestein DL Lappé BM Whiting MJ Kolek JL Clarke BC James JL Anderson 2006 Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study J Thromb Thrombolysis 22 3 191 197 1:CAS:528:DC%2BD28Xht1yis7vM 10.1007/s11239-006-9030-7 17111199 (Pubitemid 44857780)
4. T Li CY Chang DY Jin PJ Lin A Khvorova DW Stafford 2004 Identification of the gene for vitamin K epoxide reductase Nature 427 6974 541 544 1:CAS:528:DC%2BD2cXpsFWhuw%3D%3D 10.1038/nature02254 14765195 (Pubitemid 38209111)
5. G D'Andrea RL D'Ambrosio P Di Perna M Chetta R Santacroce V Brancaccio E Grandone M Margaglione 2005 A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin Blood 105 2 645 649 10.1182/blood-2004-06-2111 15358623 (Pubitemid 40070748)
6. P Weiss H Halkin S Almog 1986 The negative impact of biological variation in the effect and clearance of warfarin on methods for prediction of dose requirements Thromb Haemost 56 3 371 375 1:STN:280:DyaL2s7nvV2juw%3D%3D 3563968
7. JL Anderson BD Horne SM Stevens AS Grove S Barton ZP Nicholas SF Kahn HT May KM Samuelson JB Muhlestein JF Carlquist 2007 Couma-Gen investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation Circulation 116 22 2563 2570 1:CAS:528:DC%2BD2sXhtlagsb3F 10.1161/CIRCULATIONAHA.107.737312 17989110 (Pubitemid 350179221)
8. MW Linder S Looney JE Adams III, et al. 2002 Warfarin dose adjustments based on CYP2C9 genetic polymorphisms J Thromb Thrombolysis 14 3 227 232 1:CAS:528:DC%2BD3sXlvF2rt7s%3D 10.1023/A:1025052827305 12913403 (Pubitemid 37069306)
9. EA Millican PA Lenzini PE Milligan L Grosso C Eby E Deych G Grice JC Clohisy RL Barrack RS Burnett D Voora S Gatchel A Tiemeier BF Gage 2007 Genetic-based dosing in orthopedic patients beginning warfarin therapy Blood 110 5 1511 1515 1:CAS:528:DC%2BD2sXhtVSgsb3N 10.1182/blood-2007-01-069609 17387222 (Pubitemid 47443966)
10. E Krynetskiy P McDonnell 2007 Building individualized medicine: prevention of adverse reactions to warfarin therapy J Pharmacol Exp Ther 322 2 427 434 1:CAS:528:DC%2BD2sXoslSjtrc%3D 10.1124/jpet.106.117952 17496169 (Pubitemid 47105770)
11. MD Caldwell T Awad JA Johnson BF Gage M Falkowski P Gardina J Hubbard Y Turpaz TY Langaee C Eby CR King A Brower JR Schmelzer I Glurich HJ Vidaillet SH Yale K Qi Zhang RL Berg JK Burmester 2008 CYP4F2 genetic variant alters required warfarin dose Blood 111 8 4106 4112 1:CAS:528:DC%2BD1cXkvFeis7g%3D 10.1182/blood-2007-11-122010 18250228
12. M Wadelius LY Chen N Eriksson S Bumpstead J Ghori C Wadelius D Bentley R McGinnis P Deloukas 2007 Association of warfarin dose with genes involved in its action and metabolism Hum Genet 121 1 23 34 1:CAS:528:DC%2BD2sXhsFCgs78%3D 10.1007/s00439-006-0260-8 17048007 (Pubitemid 46421137)
13. P Borgiani C Ciccacci V Forte S Romano G Federici G Novelli 2007 Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians Pharmacogenomics 8 11 1545 1550 1:CAS:528:DC%2BD1cXntlegtw%3D%3D 10.2217/14622416.8.11.1545 18034619 (Pubitemid 350286398)
14. R Loebstein M Vecsler D Kurnik N Austerweil E Gak H Halkin S Almog 2005 Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9 Clin Pharmacol Ther 77 5 365 372 1:CAS:528:DC%2BD2MXktFCrt7Y%3D 10.1016/j.clpt.2005.01.010 15900282 (Pubitemid 40719265)
15. KL Berkner KW Runge 2004 The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis J Thromb Haemost 2 12 2118 2132 1:CAS:528:DC%2BD2MXmtFyiug%3D%3D 10.1111/j.1538-7836.2004.00968.x 15613016 (Pubitemid 40185771)
16. J Saupe MJ Shearer M Kohlmeier 1993 Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis Am J Clin Nutr 58 204 208 1:STN:280: DyaK3szjtF2quw%3D%3D 8393269
17. M Kohlmeier A Salomon J Saupe MJ Shearer 1996 Transport of vitamin K to bone in humans J Nutr 126 1192S 1196S 1:CAS:528:DyaK28XhvFansbw%3D 8642455
18. F Tokunaga S Wakabayashi T Koide 1995 Warfarin causes the degradation of protein C precursor in the endoplasmic reticulum Biochemistry 34 4 1163 1170 1:CAS:528:DyaK2MXjt1Siu7Y%3D 10.1021/bi00004a009 7827066
19. N Wajih DC Sane SM Hutson R Wallin 2004 The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats J Biol Chem 279 25276 25283 1:CAS:528:DC%2BD2cXksFygsrg%3D 10.1074/jbc.M401645200 15075329 (Pubitemid 38756780)
20. J Seidegård JW DePierre 1983 Microsomal epoxide hydrolase. Properties, regulation and function Biochim Biophys Acta 695 3-4 251 270 6418203
21. MG McDonald MJ Rieder M Nakano CK Hsia AE Rettie 2009 CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant Mol Pharmacol 75 6 1337 1346 1:CAS:528:DC%2BD1MXmvVWqsb8%3D 10.1124/mol.109.054833 19297519
22. F Takeuchi R McGinnis S Bourgeois C Barnes N Eriksson N Soranzo P Whittaker V Ranganath V Kumanduri W McLaren L Holm J Lindh A Rane M Wadelius P Deloukas 2009 A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose PLoS Genet 5 3 e1000433 10.1371/journal.pgen.1000433 19300499
23. TM Morgan HM Krumholz RP Lifton JA Spertus 2007 Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study JAMA 297 1551 1561 1:CAS:528:DC%2BD2sXktFeisbw%3D 10.1001/jama.297.14.1551 17426274 (Pubitemid 46588368)
24. RA Hegle 2002 SNP judgements and freedom of association Arterioscler Thromb Vasc Biol 22 1058 1061 10.1161/01.ATV.0000026801.56080.14 (Pubitemid 34764850)
25. JP Ioannidis EE Ntzani TA Trikalinos DG Contopoulos-Ioannidis 2001 Replication validity of genetic association studies Nat Genet 29 306 309 1:CAS:528:DC%2BD3MXotlWgsLs%3D 10.1038/ng749 11600885 (Pubitemid 33096456)
26. JL Anderson JF Carlquist BD Horne PN Hopkins 2007 Progress in unraveling the genetics of coronary artery disease and myocardial infarction Curr Atheroscler Rep 9 3 179 186 1:CAS:528:DC%2BD2sXhtlWnt73I 10.1007/s11883-007- 0017-4 18241611 (Pubitemid 47629065)